Khairulorama. Life and Work Notes.

Learn, Study, Create

Benlysta ( Belimumab) for treatment of SLE

leave a comment »

I am saluting to GSK today. Belumimab a new class of, a fully human monoclonal antibody that inhibit the B- lymphocytes stimulator ( BlyS).

A new and approved class of drugs in the U.S for the treatment of Systemic Lupus Erythmatosis.  BLyS plays a key role in B lymphocyte differentiation, survival and activation.

Mechanism of action as proposed in the BENLYSTA website

Belimumab blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. Belimumab does not bind B cells directly, but by binding BLyS, belimumab inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. BLyS is a naturally occurring protein which was discovered by HGS in 1996.


Now I know why i learn Immunology and Haematology!


Still have to read on abiximab, rituximab and omalizumab!!


Written by M Khairul Z

March 12, 2011 at 9:07 am

Posted in Uncategorized

Tagged with

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: